

# Modulation of Alzheimer's amyloid $\beta$ peptide oligomerization and toxicity by extracellular Hsp70

Isabel Rivera<sup>1,2</sup> · Ricardo Capone<sup>1</sup> · David M. Cauvi<sup>1</sup> · Nelson Arispe<sup>3</sup> · Antonio De Maio<sup>1</sup>

Received: 30 June 2017 / Revised: 9 August 2017 / Accepted: 10 August 2017 / Published online: 27 September 2017  
© Cell Stress Society International 2017

**Abstract** Alzheimer's disease (AD) is a progressive neurodegenerative disorder leading to dementia caused by advanced neuronal dysfunction and death. The most significant symptoms of AD are observed at late stages of the disease when interventions are most likely too late to ameliorate the condition. Currently, the predominant theory for AD is the "amyloid hypothesis," which states that abnormally increased levels of amyloid  $\beta$  ( $A\beta$ ) peptides result in the production of a variety of aggregates that are neurotoxic. The specific mechanisms for  $A\beta$  peptide-induced cytotoxicity have not yet been completely elucidated. However, since the majority of  $A\beta$  is released into the extracellular milieu, it is reasonable to assume that toxicity begins outside the cells and makes its way inside where it disrupts the basic cellular process resulting in cell death. There is increasing evidence that hsp, particularly Hsp70, are exported into the extracellular milieu by an active export mechanism independent of cell death. Therefore, both  $A\beta$  peptides and Hsp70 may coexist in a common

environment during pathological conditions. We observed that Hsp70 affected the  $A\beta$  assembling process in vitro preventing oligomer formation. Moreover, the presence of Hsp70 reduced the  $A\beta$  peptide-induced toxicity of cultured neurons (N2A cells). These results suggest a potential mechanism for the reduction of the detrimental effects of  $A\beta$  peptides in AD.

**Keywords** Alzheimer's disease · Amyloid  $\beta$  · Heat shock proteins · Hsp70 · Neurons · Cytotoxicity

## Introduction

Alzheimer's disease (AD) is a progressive neurodegenerative disorder resulting in dementia due to advanced neuron dysfunction and death. The cost of AD treatment is a major expense for the healthcare system and is expected to rise in the future with the upsurge of the aging population (Cummings et al. 2017). In addition, the development of AD is a major emotional, social, and economic burden for the patient's family members who provide most of the care (Crews and Masliah 2010; Lobello et al. 2012). Except for genetic forms, there are no current early predictors or diagnostics for the onset of AD. The most perceivable symptoms are observed when the patient is already in the late stages of the disease, making any treatment difficult. AD is a multifactorial condition modulated by several confounding factors, including genetics, ethnicity, sex, environment, physiology, and trauma (Crews and Masliah 2010; Lobello et al. 2012). Currently, the predominant theory for the incidence of AD is the "amyloid hypothesis," that states that abnormal levels of amyloid  $\beta$  ( $A\beta$ ) peptides result in the production of cytotoxic complexes (Benilova et al. 2012).  $A\beta$  peptides are produced

---

✉ Antonio De Maio  
ademaio@ucsd.edu

<sup>1</sup> Division of Trauma, Critical Care, Burns and Acute Care Surgery, Department of Surgery and Department of Neurosciences, School of Medicine, University of California San Diego, 9500 Gilman Drive, #0739, La Jolla 92093-0739, CA, USA

<sup>2</sup> Initiative for Maximizing Student Development (IMSD) Program, University of California San Diego, La Jolla, CA, USA

<sup>3</sup> Department of Anatomy, Physiology and Genetics, Uniformed Services University School of Medicine, 4301 Jones Bridge Road, Bethesda, MD 20814, USA

by cleavage from the membrane-anchored amyloid  $\beta$  precursor protein (APP) by several proteases, but predominantly by  $\beta$  and  $\gamma$  secretases, leading mostly to  $A\beta$  peptides and fragments (Thinakaran and Koo 2008). Once in the external milieu,  $A\beta$  peptides follow a natural aggregation process resulting in a variety of oligomeric forms that act as active neurotoxins, causing neuronal dysfunction, loss of synaptic connections, and cell death.  $A\beta$  peptides are also the main precursor of amyloid plaques that are the hallmark for the postmortem diagnosis of AD (Haass and Selkoe 2007). The toxicity of  $A\beta$  complexes appears to be mediated by small oligomers rather than by the higher molecular weight aggregates, protofibrils, and fibers (Bieschke et al. 2011).  $A\beta$  peptide cytotoxicity has been associated with increases in intracellular calcium levels, production of oxygen radicals, lipid peroxidation, mitochondrial dysfunction, and inflammation (Crews and Masliah 2010; Lobello et al. 2012). In addition,  $A\beta$  peptide oligomers interact with the plasma membranes forming ion conductance pathways, called the  $A\beta$  channels (Arispe et al. 1993a, b), which appear to be responsible for cellular toxicity (Simakova and Arispe 2006). Based on these observations, it is likely that  $A\beta$  toxicity begins outside the cells and makes its way inside to disrupt basic cellular processes. Therefore, ideal therapeutic interventions should be directed at the early stages of the oligomerization process to prevent extracellular  $A\beta$  peptide-induced cytotoxicity.

There is extensive evidence suggesting that the expression of heat shock proteins (hsp) protects cells from  $A\beta$  peptide toxicity (Kirby et al. 1994; Muchowski and Wacker 2005; Brown 2007; King et al. 2009; Hoshino et al. 2011; Toth et al. 2013; Bobkova et al. 2014). Hsp include a large family of well-conserved proteins that are classified by their molecular mass. The Hsp70 family of hsp is composed of Hsp70 (HSPA1A), the major stress-inducible form, whereas other Hsp70s such as Hsc70 (HSPA8) and Grp78 (BIP, HSPA5) are constitutively expressed (Lindquist and Craig 1988; De Maio 1999; Kampinga et al. 2009). The expression of Hsp70 after heat shock in the brain is different between neurons in the cerebellum and hippocampus (Sprang and Brown 1987). Moreover, glial cells and neurons expressed different levels of Hsp70 and Hsc70 (Brown 2007; Marini et al. 1990; Chow et al. 2014). The mechanism for hsp protection from  $A\beta$  peptide toxicity has not been elucidated. Since hsp are molecular chaperones playing a key role in protein folding and solubilization of misfolded polypeptides, it has been assumed that they might modulate  $A\beta$  peptide oligomerization. However, there is a compartmental discrepancy with this assumption. Hsp are present in the cytosol and other subcellular compartments, such as ER and mitochondria, whereas the toxic forms of  $A\beta$  peptides are located outside cells. This discrepancy has been solved by evidence demonstrating that hsp could be detected outside cells (Hightower and Guidon 1989; De Maio 2011), exported by either an active

mechanism or released after necrotic cell death (De Maio and Vazquez 2013; Gastpar et al. 2005). Extracellular hsp have been shown to play multiple roles, including stimulation of immune cells, activation of phagocytosis, and interaction with extracellular protein complexes, a process that has been named the stress observation system (De Maio 2011). Consequently, the export of Hsp70 could ameliorate  $A\beta$  peptide toxicity by preventing their oligomerization and/or interfering with the interaction of  $A\beta$  oligomers with cells. In this investigation, we tested this hypothesis and found that indeed Hsp70 interferes with  $A\beta$  peptide oligomerization preventing the formation of the cytotoxic complexes.


## Methods

### Monomerization and oligomerization of $A\beta_{1-42}$ peptides

$A\beta_{1-42}$  peptides were monomerized by incubation with hexafluoroisopropanol (HFIP) as previously described (Capone et al. 2009). Briefly, 5 mg of  $A\beta_{1-42}$  peptides (Bachem, cat# H1368) was resuspended in 1.5 mL of HFIP (Regis, cat# 270702) and gently shaken for over 20 h at room temperature. Two volumes of water (3 mL) were added and the solution was immediately aliquoted into glass vials (125  $\mu$ g/vial) prestanding on a dry ice/acetone bath until fully frozen. The frozen aliquots were lyophilized for 72 h at maximum vacuum (0.021 mbar), which was terminated by exposure to dry prefiltered argon gas and stored at  $-80$  °C. Before use, monomerized  $A\beta_{1-42}$  peptides were thawed in ice and dissolved in water. The addition of water is counted as time zero since aggregation starts immediately.

### $A\beta_{42}$ aggregation in the presence of hsp proteins

Monomerized  $A\beta_{1-42}$  peptides (1  $\mu$ g) were incubated in the absence or in the presence of increasing concentrations of Hsp70, Hsc70, Grp78, and Hsp40 dissolved in 4.5 mM Tris pH 7.4. Incubations were initially set on ice followed by incubations at 37 °C for 24 h, after which reactions were frozen in  $-80$  °C until analysis. Samples were thawed on ice and 5  $\mu$ L of LDS sample buffer 4 $\times$  (NuPAGE) was added, mixed, not boiled, and loaded into 4–12% Bis-Tris gradient gels (Novex, 1.5 mm  $\times$  10 wells), run at 200 V for 50–53 min in MOPS SDS running buffer. Gels were transferred to nitrocellulose membranes using Bolt transfer buffer at 30 V for 1 h. Membranes were blocked with 5% BSA dissolved in TBS-Tween 0.1% for 2 h and incubated overnight with mouse anti- $A\beta$  mAb 4G8 (Covance) at a concentration of 1  $\mu$ g/mL in 5% BSA at 4 °C with moderate shaking, rinsed 3 times with TBS-T, and incubated for 1 h at RT with anti-mouse conjugated to HRP (ThermoFisher)



**Fig. 1** Oligomerization of A $\beta$  peptides at different temperatures. Monomerized A $\beta_{1-42}$  peptides (1  $\mu$ g) were kept as a monomer (lane 1) or were incubated at 37 °C (lane 2), 25 °C (lane 3), or 4 °C (lane 4), for 20 h in 4.5 mM Tris pH 7.4. Samples were electrophoresed, transferred onto nitrocellulose membranes, and analyzed by Western blotting using Clone 4G8 antibody followed by an HRP-conjugated secondary antibody

diluted 1:1000 and rinsed 3 times with TBS-T. Images were developed using ECL (Pierce, SuperSignal) and acquired using a BioRad detection system under linear conditions of detection. Then, blots were stripped using Re-Blot Plus Mild (Millipore) for 20 min, treated as above but incubated with 1:1000 dilutions of rabbit anti-Hsp70 (ADI-SPA-812), rat anti-Hsc70 (ADI-SPA-815), rabbit anti-Grp78 (StressMarq, SPC-180), and rabbit anti-Hsp40

(Cell Signal # 48685) and secondary antibodies (ThermoFisher #32460 and Invitrogen #619520).

**Cell viability by flow cytometry**


N2A neuroblastoma cells were incubated or not with A $\beta_{1-42}$  peptides in DMEM medium (1% FBS) at 37 °C for 48 h. Cells were then harvested and stained with APC-conjugated annexin V and propidium iodide (PI) for flow cytometry analysis.


**Results**

**The degree of A $\beta_{1-42}$  peptide oligomerization induced different forms of cellular toxicity**

A $\beta_{1-42}$  peptides were monomerized by incubation with HFIP followed by extensive lyophilization to eliminate the solvent. Then, the monomeric A $\beta_{1-42}$  peptides (4.5 kDa) were incubated at 37, 25, or 4 °C for 20 h. Samples were electrophoresed and analyzed by Western blotting using Clone 4G8 antibody. HFIT treatment indeed resulted in the monomerization of A $\beta_{1-42}$  peptides, as illustrated in Fig. 1 (lane 1). Incubation of the monomeric peptides at 37 °C resulted in the appearance of oligomers between 52 and 150 kDa (Fig. 1, lane 2), whereas incubation at 25 °C decreased the intensity of the oligomeric signal (Fig. 1, lane 3) and no oligomers were detected after incubation at 4 °C (Fig. 1, lane 4). N2A cells (mouse neuroblastoma) were initially

**Fig. 2** A $\beta$  peptides induced cell death of N2A neuroblastoma cells. N2A cells were incubated in DMEM medium containing 1% FBS at 37 °C for 48 h in the absence or presence of two concentrations (5 and 10  $\mu$ M) of monomerized or pre-oligomerized A $\beta_{1-42}$  peptides. Cell death was evaluated by annexin V and propidium iodide staining and flow cytometry analysis





**Fig. 3** Hsp70 interferes with the oligomerization of A $\beta$  peptides. Monomerized A $\beta_{1-42}$  peptides (1  $\mu$ g) were kept as a monomer (lane 1), or incubated at 37 °C for 20 h (lane 2), or were incubated with various concentrations of Hsp70 (from 0.1 to 2.06  $\mu$ g) in 4.5 mM Tris pH 7.4 at 37 °C for 24 h (lanes 3–8). Samples were electrophoresed, transferred onto nitrocellulose membranes, and analyzed by Western blotting using Clone 4G8 antibody followed by an HRP-conjugated secondary antibody. Membranes were stripped and incubated with 1:1000 dilutions of rabbit anti-Hsp70 (ADI-SPA-812), followed by an HRP-conjugated secondary antibody

incubated with A $\beta_{1-42}$  peptides, in the monomeric or pre-oligomerized forms, at a concentration of 5 or 10  $\mu$ M, which have been widely used in prior studies (Simakova and Arispe 2006, 2007), in DMEM medium containing 1% FBS at 37 °C for 48 h. Cell viability was monitored by staining with annexin V and PI and analyzed by flow cytometry. Cell death, as indicated by the appearance of annexin V and PI-positive signals, was more prominent at 10  $\mu$ M (Fig. 2, bottom panel) than at 5  $\mu$ M (Fig. 2, top panel). Exposure of cells to the initial monomeric forms, which form oligomers upon incubation with the cells, showed a higher level of cell death in comparison with cells incubated with the pre-oligomerized peptides (Fig. 2). A typical apoptotic pattern of cell death was observed after incubation with A $\beta_{1-42}$  peptide monomers, as indicated by initial staining with annexin V followed by membrane permeabilization as indicated by PI uptake (Fig. 2, middle panel). In contrast, cells


incubated with the pre-oligomerized peptides displayed a sharp increase in the staining of both annexin V and PI simultaneously, suggesting that cells are not dying of apoptosis, but rather by a necrotic-like process (Fig. 2, right panel).

### Hsp70 altered A $\beta$ peptide oligomerization and reduced cellular toxicity

A $\beta_{1-42}$  peptides in the monomeric form were incubated with increasing concentrations of Hsp70 at 37 °C for 20 h in the absence of nucleotides. As controls, A $\beta_{1-42}$  peptides were maintained either as a monomer or oligomerized at 37 °C. All samples were analyzed by Western blotting. The addition of Hsp70 to A $\beta$  monomers resulted in a reduction of the oligomerization process (Fig. 3), even when the molecular ratio between Hsp70 and A $\beta_{1-42}$  peptides was 1:150. Although the addition of Hsp70 to A $\beta_{1-42}$  peptides resulted in inhibition of large molecular weight complexes, it did not apparently affect the presence of dimer, trimer, and tetramer complexes (Fig. 3). Then, N2A cells were incubated with Hsp70 (0.2  $\mu$ M) alone, A $\beta_{1-42}$  peptide monomers (10  $\mu$ M), or a combination of A $\beta_{1-42}$  peptide monomers and Hsp70 (1:50 ratio) at 37 °C for 48 h. A reduction in 50% of cell mortality was observed in cells co-incubated with A $\beta_{1-42}$  peptides and Hsp70 in comparison with cells incubated with A $\beta_{1-42}$  peptides alone (Fig. 4). A second addition of Hsp70 (0.32  $\mu$ g, 0.4  $\mu$ M final) after 24 h of co-incubation with A $\beta_{1-42}$  peptides and Hsp70 resulted in a further decrease of cell death (70%) as opposed to cells incubated with A $\beta_{1-42}$  peptides alone (Fig. 4). No toxic effect was observed by incubation of cells with Hsp70 (0.2  $\mu$ M) alone (Fig. 4). At the end of the incubation process (48 h), the extracellular medium of cells exposed to A $\beta_{1-42}$  peptides and Hsp70 as described above was collected, and the presence of A $\beta_{1-42}$  forms was detected by Western blotting. Oligomerization of A $\beta$  was observed in samples collected from cells that were initially incubated with monomeric A $\beta_{1-42}$  alone (Fig. 5, lane 3), indicating that the monomers formed oligomers during incubation conditions with cells at 37 °C. In contrast, the presence of A $\beta_{1-42}$  oligomers was significantly reduced in medium of cells co-incubated with A $\beta_{1-42}$  peptides and Hsp70 (Fig. 5, lanes 4 and 5). This observation corroborates that Hsp70 interferes with A $\beta_{1-42}$  peptide oligomerization, therefore, resulting in reduced cell toxicity.


### The addition of Hsp70 did not affect the toxicity of pre-oligomerized A $\beta$ peptides

A $\beta_{1-42}$  peptide monomers (Fig. 6, lane 1) were incubated in the absence (Fig. 6, lane 2) or presence of Hsp70 (Fig. 6, lane 2), at a ratio of 1 to 50 between Hsp70 and A $\beta_{1-42}$




**Fig. 4** Hsp70 reduces  $A\beta$  peptide-induced cellular toxicity. N2A cells were incubated with Hsp70 (0.2  $\mu$ M) alone,  $A\beta_{1-42}$  peptide monomers (10  $\mu$ M), or a combination of  $A\beta_{1-42}$  peptide monomers and Hsp70 (10 and 0.2  $\mu$ M, respectively, 1 treatment) at 37  $^{\circ}$ C for 48 h. In some experiments, a second dose of Hsp70 (0.2  $\mu$ M, 2 treatments) was added after 24 h

of co-incubation with  $A\beta_{1-42}$  peptides and Hsp70. Cell death was evaluated by annexin V and propidium iodide staining and flow cytometry analysis. Upper panels show representative annexin V/PI density plots for each condition, and the lower panel shows histograms representing annexin V-positive cells



**Fig. 5**  $A\beta$  peptides are oligomerized during incubation with cells and reduced by co-incubation with Hsp70. Cells (N2A) were incubated in DMEM medium containing 1% FBS at 37  $^{\circ}$ C for 48 h in the absence (lane 1) or presence of Hsp70 (0.32  $\mu$ g) (lane 2). Cells were also incubated with monomerized  $A\beta_{1-42}$  peptides (10  $\mu$ M) (lane 3) or co-incubated with Hsp70 (0.32  $\mu$ g) added on day 1 or added on days 1 (lane 4) and 2 (lane 5). At the end of the incubation period, the extracellular medium was collected, depleted of any floating cells by centrifugation and electrophoresed, transferred onto nitrocellulose membranes, and analyzed by Western blotting using Clone 4G8 antibody followed by an HRP-conjugated secondary antibody

peptides, respectively, at 37  $^{\circ}$ C for 20 h. In addition, pre-oligomerized  $A\beta_{1-42}$  peptide complexes were incubated with Hsp70 at 37  $^{\circ}$ C for 20 h (Fig. 6, lane 4). Samples were electrophoresed and analyzed by Western blotting. As previously shown, the addition of Hsp70 interfered with  $A\beta_{1-42}$  peptide oligomerization. However, the addition of Hsp70 after  $A\beta_{1-42}$  peptide oligomerization did not reverse the process. It is important to note that the incubation of Hsp70 and  $A\beta_{1-42}$  peptides was performed in the absence of nucleotides. Then, N2A cells were exposed to  $A\beta_{1-42}$  peptides (5  $\mu$ M) that were oligomerized in the absence or presence of Hsp70 (0.2  $\mu$ M), or with  $A\beta_{1-42}$  peptides (5  $\mu$ M) that were incubated with Hsp70 (0.2  $\mu$ M) after the oligomerization process, and all incubations were carried out at 37  $^{\circ}$ C for 48 h. A dramatic reduction in cell death (90%) was observed when cells were incubated with medium containing pre-oligomerized  $A\beta_{1-42}$  peptides in the presence of Hsp70 as opposed to cells incubated with pre-oligomerized  $A\beta_{1-42}$  peptides in the absence of Hsp70 (Fig. 7). In contrast, the addition of Hsp70 after oligomerization of  $A\beta_{1-42}$  peptides displayed the same level of toxicity as pre-oligomerized  $A\beta$  peptides alone (Fig. 7). No toxic effect was observed after the addition of Hsp70 in the absence of  $A\beta$  peptides (Fig. 7).



**Fig. 6** Hsp70 interferes with the oligomerization of A $\beta$  peptides but does not affect pre-oligomerized peptides. Monomerized A $\beta_{1-42}$  peptides (1  $\mu$ g) were kept as a monomer (lane 1), or incubated at 37 °C for 20 h (lane 2), or incubated with Hsp70 (0.32  $\mu$ g) in 4.5 mM Tris pH 7.4 at 37 °C for 20 h. Oligomerized A $\beta_{1-42}$  peptides (1  $\mu$ g) were incubated with Hsp70 (0.32  $\mu$ g) in 4.5 mM Tris pH 7.4 at 37 °C for 20 h (lane 4). Samples were electrophoresed, transferred onto nitrocellulose membranes, and analyzed by Western blotting using Clone 4G8 antibody followed by an HRP-conjugated secondary antibody. Membranes were stripped and incubated with 1:1000 dilutions of rabbit anti-Hsp70 (ADI-SPA-812), followed by an HRP-conjugated secondary antibody

### Other members of the Hsp70 family also interfered with A $\beta$ peptide oligomerization


Based on the prior observations indicating that Hsp70 reduced A $\beta_{1-42}$  oligomerization in *in vitro* conditions, it was important to test whether this effect was specific to other members of the Hsp70 family. Monomeric A $\beta_{1-42}$  peptides were incubated with various concentrations of Hsc70 (HSPA8) or Grp78 (HSPA5) at 37 °C for 20 h. In addition, A $\beta$  peptides were incubated with Hsp40 (DNAJB1) in the same conditions described above. The products of the incubations were analyzed by Western blotting. All members of the Hsp70 family (Hsc70 and Grp78) reduced the oligomerization of A $\beta_{1-42}$  peptides in a concentration-dependent manner (Fig. 8a, b). In contrast, Hsp40 did not affect the oligomerization process of A $\beta_{1-42}$  (Fig. 8c).

### Discussion

AD is likely to become the major health problem of the current century due to the growth of the aging population, the

increasing cost to the healthcare system, and the social and emotional burden for relatives and caregivers (Crews and Masliah 2010; Lobello et al. 2012; Cummings et al. 2017). Therapeutic interventions to ameliorate the incidence of AD are not envisioned in the near future since the initial causes and manifestations of AD are not well understood. The current theory for the incidence of AD is the “amyloid hypothesis,” indicating that increasing levels of A $\beta$  peptides are responsible for neuronal toxicity (Benilova et al. 2012). A $\beta$  peptides are prone to aggregate very rapidly, probably due to a conformational change forming  $\beta$ -sheet-rich structures that stabilize within oligomeric complexes of different sizes that eventually develop into amyloid-type fibrils that accumulate in the brain and correspond to the most widely known hallmark of AD (Bitan et al. 2003; Haass and Selkoe 2007; Roychaudhuri et al. 2009). A $\beta$  peptide intermediates have been shown to be transient and heterogeneous with some displaying an annular pore-like structure (Kotler et al. 2014). The major peptides that are released from cells correspond to A $\beta_{1-40}$  and A $\beta_{1-42}$  that displayed differences in their aggregation process and cytotoxicity (Bitan et al. 2003; Fu et al. 2017). Currently, it has been proposed that A $\beta$  oligomeric complexes show differences in their cytotoxicity with the low molecular weight oligomers being the most toxic (Lambert et al. 1998; Kirkitadze et al. 2002; Dahlgren et al. 2002; Zhao et al. 2012).

In the present study, we compare the cytotoxicity of monomeric or pre-oligomerized forms of A $\beta_{1-42}$  peptides, finding that both complexes induced N2A cell death after incubation at 37 °C for 48 h. Moreover, the monomeric forms of A $\beta_{1-42}$  were observed to oligomerize within the culture medium during the incubation period at 37 °C, perhaps resulting in low molecular weight cytotoxic complexes. Although toxicity was observed after incubation with both monomers and pre-oligomers, cell death was elevated when cells were initially exposed to A $\beta_{1-42}$  peptide monomers as opposed to pre-oligomerized complexes. Moreover, it appears that incubation with A $\beta_{1-42}$  monomers induced cell death by apoptosis, whereas exposure to pre-oligomerized complexes induced a necrotic-like process. The trigger of apoptosis after exposure to A $\beta_{1-42}$  monomers may be related to an increase in intracellular calcium levels, as it has been previously reported (Arispe et al. 2007; Lin and Arispe 2015). In this regard, extensive studies have shown that low molecular weight A $\beta$  complexes get incorporated in both artificial and in natural membranes opening ion conductance pathways or channels (Arispe et al. 1993a, b, 1996; Kawahara et al. 1997; Capone et al. 2009), that are selective for calcium (Arispe et al. 1993b, 1996). Thus, we speculate that incubation of cells with A $\beta$  monomers resulted in a slow production of low molecular weight complexes that get inserted in the plasma membrane opening a channel activity, increasing the flow of calcium inside the cells activating the apoptotic process. The proposed structures for these A $\beta$  channels are annular oligomeric conformation



**Fig. 7** Hsp70 improves A $\beta$  peptide-induced cellular toxicity only by preventing the formation of A $\beta$  peptide oligomers. N2A cells were exposed to A $\beta_{1-42}$  peptides (5  $\mu$ M) monomers in the absence (A $\beta$ ) or presence of Hsp70 (0.2  $\mu$ M, A $\beta$ +Hsp70 pre-I), or with oligomerized A $\beta_{1-42}$  peptides (5  $\mu$ M) incubated with Hsp70 (0.2  $\mu$ M, A $\beta$ +Hsp70 post-I) after the oligomerization process. All incubations were carried


out at 37  $^{\circ}$ C for 48 h. Hsp70 toxicity in the absence of A $\beta$  peptides was also tested by incubating N2A cells with Hsp70 (0.2  $\mu$ M, Hsp70) at 37  $^{\circ}$ C for 48 h. Cell death was evaluated by annexin V and propidium iodide staining and flow cytometry analysis. Upper panels show representative annexin V/PI density plots for each condition, and the lower panel shows histograms representing annexin V-positive cells

formed by intermediate oligomers (Durell et al. 1994; Arispe et al. 2010; Shafirir et al. 2010a, b; Connelly et al. 2012; Lee et al. 2016; Jang et al. 2010). High molecular weight A $\beta$  peptide complexes could also interact with cell membranes but result in the formation of larger nonselective pores that induce cell death by necrosis. This idea was previously considered when comparing the effect of aggregates from freshly prepared A $\beta$  peptide solutions to larger aggregates from aged A $\beta$  peptide solutions (Simakova and Arispe 2006). These aged aggregates produce nonselective increases in membrane permeability, which permits the passage of molecules greater than the size cutoff for most ion channels. Other studies suggested that membrane disruption by A $\beta$  peptides occurs by a two-step process, with the initial formation of ion-selective pores followed by nonspecific, noncation selective, fragmentation of the lipid membrane during amyloid fiber formation (Sciacca et al. 2012).

Our studies indicate that the cytotoxicity of A $\beta$  peptides builds up during the process of oligomerization. Therefore, interfering with this process may be critical to reducing the neuron degeneration that is associated with the development of AD. Prior studies have shown that induction of the stress response and expression of hsp resulted in protection from A $\beta$  peptide toxicity (Kirby et al. 1994; Muchowski and Wacker

2005; Brown 2007; King et al. 2009; Hoshino et al. 2011; Toth et al. 2013; Bobkova et al. 2014). In these investigations, the assumption was that Hsp70 as a molecular chaperone could indeed interrupt A $\beta$  peptide oligomerization. However, hsp are mainly localized in the intracellular compartments, separating them from the toxic A $\beta$  peptides that are present in the extracellular environment. This potential discrepancy is resolved by the increasing evidence that hsp are present outside cells (Hightower and Guidon 1989; De Maio 2011). Therefore, it is possible that the protective effect of hsp is related to their export into the extracellular milieu. We tested this hypothesis and certainly found that Hsp70 could interfere with A $\beta$  peptide oligomerization in vitro reducing cytotoxicity in culture conditions. The reduction in A $\beta$  peptide oligomerization after incubation with Hsp70 echoes prior observations in vitro (Evans et al. 2006). In contrast, the addition of Hsp70 to pre-oligomerized A $\beta$  peptides neither disperses the oligomeric complexes nor decreases cytotoxicity. Other studies have shown that the release of Hsp70 into the extracellular milieu by glial cells conferred protection to neighboring neurons (Guzhova et al. 2001). Recent investigations using a modified Hsp70 containing a secretory signal that allows the protein to be secreted also showed protection in a *Drosophila* model of AD (Fernandez-Funez et al. 2016). In addition,

**Fig. 8** Hsc70 and Grp78 interfere with the oligomerization of A $\beta$  peptides. Monomerized A $\beta_{1-42}$  peptides (1  $\mu$ g) were kept as a monomer (lane 1), or incubated at 37 °C for 20 h (lane 2), or incubated with various concentrations of **a** Hsc70 (from 0.1 to 2.12  $\mu$ g) (lanes 3–8), **b** Grp78 (from 0.1 to 2  $\mu$ g) (lanes 3–8), or **c** Hsp40 (from 0.1 to 1.18  $\mu$ g) (lanes 3–8), in 4.5 mM Tris pH 7.4 at 37 °C for 24 h. Samples were electrophoresed, transferred onto nitrocellulose membranes, and analyzed by Western blotting using Clone 4G8 antibody followed by an HRP-conjugated secondary antibody. Membranes were stripped and incubated with 1:1000 dilutions of rat anti-Hsc70 (ADI-SPA-815), rabbit anti-Grp78 (StressMarq, SPC-180), or rabbit anti-Hsp40 (Cell Signal # 48685) and the respective secondary HRP-conjugated secondary antibody




exogenous intranasal administration of Hsp70 reached the brain and ameliorated some symptoms associated with AD in a mouse model (Bobkova et al. 2014).

A major finding from our studies is that the inhibition of A $\beta_{1-42}$  oligomerization could be observed at a molar ratio 1:150 between Hsp70 and A $\beta_{1-42}$ , in the absence of nucleotides. A similar substoichiometric phenomenon was observed in the inhibition of A $\beta$  fiber formation by Hsp70 in an ATP-dependent fashion (Evans et al. 2006). Our observations are not compatible with a chaperone activity for Hsp70 in which

one Hsp70 binds to one A $\beta_{1-42}$  peptide in a nucleotide-dependent manner. An alternative is that Hsp70 interferes with the conversion of small A $\beta$  peptide complexes (dimers, trimers, or tetramers) into larger oligomers in a nonchaperone mode (Fig. 9). Thus, it is possible that Hsp70 interferes with an early step in the oligomerization process, which has been reported to result in a conformational change from a random coil structure to a  $\beta$ -sheet conformation assembling into oligomers of different sizes (Roche et al. 2016; Seo et al. 2017; Bobo et al. 2017). Indeed, some amyloid complexes are the product





**Fig. 9** Model of A $\beta$  peptide oligomerization and interference by Hsp70. A $\beta$  peptides and Hsp70s are released from neurons, glial cells, and astrocytes into the extracellular environment. A $\beta$  monomers are produced by enzymatic cleavage of the membrane-anchored amyloid  $\beta$  precursor protein APP. Once released, A $\beta$  initiates a very rapid

oligomerization process with the formation of dimers, trimers, and tetramers, followed by the slow assembly of large molecular weight oligomers, which are the cytotoxic complexes, and fibers. Hsp70s interfere with the assembly of these large molecular weight oligomers resulting in reduced cytotoxicity

of stable antiparallel cross- $\beta$ -sheet complexes (Balbirnie et al. 2001), which have been modulated in silico (Dorosh and Stepanova 2016). It has been hypothesized that the initial step in A $\beta$  peptide oligomerization is related to the formation of a “seed” complex that triggers the oligomerization process (Harper et al. 1997). Thus, Hsp70 may be interfering with this initial seeding step in a very efficient manner, perhaps acting as a buffer system. Therefore, the question that emerges is whether the interaction of Hsp70 with the initial seeding of A $\beta$  peptide complexes is reversible or whether Hsp70 stabilized this initial complex in a form that is incapable of further oligomerization. A study on small hsp has shown that this protein sequestered A $\beta$  oligomers into large aggregates that are not toxic. In addition, they proposed that the small hsp underwent a conformational change upon interaction with A $\beta$  peptides (Ojha et al. 2011). In contrast with these observations, we did not detect any activity of Hsp70 disrupting very large peptide aggregates. Similarly, DNAJB6 was reported to reduce the aggregation of A $\beta_{1-42}$  peptides also in a nonstoichiometric mode (Mansson et al. 2014), as we described herewith for the Hsp70 family. Interestingly, the decrease in A $\beta_{1-42}$  high molecular weight complexes by DNAJB6 was not observed by other members of the DNAJ family, including DNAJB1 (Hsp40), in agreement with our results.

Our findings also indicated that other members of the Hsp70 family, including Hsc70 and Grp78, are also capable of preventing A $\beta$  peptide oligomerization. Therefore, it is possible that the export of any Hsp70 family member during normal physiological conditions could control the oligomerization of A $\beta$  peptides. Thus, the presence of Hsp70 in the extracellular environment might help to maintain A $\beta$  peptides

in the monomeric form that could be cleared from the brain by a natural process (Fig. 9). Indeed, A $\beta$  peptides are cleared from the brain very efficiently (Shibata et al. 2000; Bu 2009; Kanekiyo et al. 2013; Liu et al. 2017). Moreover, the imbalance between production and clearance has been proposed as a cause of AD (Bu 2009; Selkoe and Hardy 2016). Thus, we can speculate that altering the balance between extracellular Hsp70 and A $\beta$  peptides may increase the level of neurotoxicity contributing to the development of AD. A disparity between A $\beta$  peptides and Hsp70 may occur during aging. Expression of hsp (Heydari et al. 1995; Pahlavani et al. 1995; Nitta et al. 1994; Faassen et al. 1989) and their circulating levels (Rea et al. 2001; Njemini et al. 2011a, b) have both been reported to decay during aging. In contrast, circulating levels of A $\beta$  peptides increased with age (Shoji et al. 2001). Consequently, it is possible that the reduction in hsp expression and the parallel increase in A $\beta$  peptide release during aging are a cause for the development of advanced neuronal dysfunction and the progression of AD.

**Acknowledgements** We would like to thank Barbara Rho for her excellent editing of the manuscript.

**Funding** This work was supported by National Institutes of Health (NIH) Grant R01 GM11447 and UC San Diego Academic Senate grant.

## References

- Arispe N, Pollard HB, Rojas E (1993a) Giant multilevel cation channels formed by Alzheimer disease amyloid beta-protein [A beta P-(1-40)] in bilayer membranes. *Proc Natl Acad Sci U S A* 90(22):10573–10577
- Arispe N, Rojas E, Pollard HB (1993b) Alzheimer disease amyloid beta protein forms calcium channels in bilayer membranes: blockade by

- tromethamine and aluminum. *Proc Natl Acad Sci U S A* 90(2):567–571
- Arispe N, Pollard HB, Rojas E (1996) Zn<sup>2+</sup> interaction with Alzheimer amyloid beta protein calcium channels. *Proc Natl Acad Sci U S A* 93(4):1710–1715
- Arispe N, Diaz JC, Simakova O (2007) Abeta ion channels. Prospects for treating Alzheimer's disease with Abeta channel blockers. *Biochim Biophys Acta* 1768(8):1952–1965
- Arispe N et al (2010) Polyhistidine peptide inhibitor of the Abeta calcium channel potentially blocks the Abeta-induced calcium response in cells. Theoretical modeling suggests a cooperative binding process. *Biochemistry* 49(36):7847–7853
- Balbirnie M, Grothe R, Eisenberg DS (2001) An amyloid-forming peptide from the yeast prion Sup35 reveals a dehydrated beta-sheet structure for amyloid. *Proc Natl Acad Sci U S A* 98(5):2375–2380
- Benilova I, Karran E, De Strooper B (2012) The toxic Abeta oligomer and Alzheimer's disease: an emperor in need of clothes. *Nat Neurosci* 15(3):349–357
- Bieschke J et al (2011) Small-molecule conversion of toxic oligomers to nontoxic beta-sheet-rich amyloid fibrils. *Nat Chem Biol* 8(1):93–101
- Bitan G et al (2003) Amyloid beta -protein (Abeta) assembly: Abeta 40 and Abeta 42 oligomerize through distinct pathways. *Proc Natl Acad Sci U S A* 100(1):330–335
- Bobkova NV et al (2014) Therapeutic effect of exogenous hsp70 in mouse models of Alzheimer's disease. *J Alzheimers Dis* 38(2):425–435
- Bobo C et al (2017) Synthetic toxic Abeta1-42 oligomers can assemble in different morphologies. *Biochim Biophys Acta* 1861(5 Pt A):1168–1176
- Brown IR (2007) Heat shock proteins and protection of the nervous system. *Ann N Y Acad Sci* 1113:147–158
- Bu G (2009) Apolipoprotein E and its receptors in Alzheimer's disease: pathways, pathogenesis and therapy. *Nat Rev Neurosci* 10(5):333–344
- Capone R et al (2009) Amyloid-beta-induced ion flux in artificial lipid bilayers and neuronal cells: resolving a controversy. *Neurotox Res* 16(1):1–13
- Chow AM et al (2014) Localization of heat shock proteins in cerebral cortical cultures following induction by celastrol. *Cell Stress Chaperones* 19(6):845–851
- Connelly L et al (2012) Atomic force microscopy and MD simulations reveal pore-like structures of all-D-enantiomer of Alzheimer's beta-amyloid peptide: relevance to the ion channel mechanism of AD pathology. *J Phys Chem B* 116(5):1728–1735
- Crews L, Masliah E (2010) Molecular mechanisms of neurodegeneration in Alzheimer's disease. *Hum Mol Genet* 19(R1):R12–R20
- Cummings J et al (2017) Alzheimer's disease drug development pipeline: 2017. *Alzheimers Dement* 3:367–384
- Dahlgren KN et al (2002) Oligomeric and fibrillar species of amyloid-beta peptides differentially affect neuronal viability. *J Biol Chem* 277(35):32046–32053
- De Maio A (1999) Heat shock proteins: facts, thoughts, and dreams. *Shock* 11(1):1–12
- De Maio A (2011) Extracellular heat shock proteins, cellular export vesicles, and the stress observation system: a form of communication during injury, infection, and cell damage. *Cell Stress Chaperones* 16(3):235–249
- De Maio A, Vazquez D (2013) Extracellular heat shock proteins: a new location, a new function. *Shock* 40(4):239–246
- Dorosh L, Stepanova M (2016) Probing oligomerization of amyloid beta peptide in silico. *Mol BioSyst* 13(1):165–182
- Durell SR et al (1994) Theoretical models of the ion channel structure of amyloid beta-protein. *Biophys J* 67(6):2137–2145
- Evans CG, Wisen S, Gestwicki JE (2006) Heat shock proteins 70 and 90 inhibit early stages of amyloid beta-(1–42) aggregation in vitro. *J Biol Chem* 281(44):33182–33191
- Faassen AE et al (1989) Diminished heat-shock protein synthesis following mitogen stimulation of lymphocytes from aged donors. *Exp Cell Res* 183(2):326–334
- Fernandez-Funez P et al (2016) Holdase activity of secreted Hsp70 masks amyloid-beta42 neurotoxicity in Drosophila. *Proc Natl Acad Sci U S A* 113(35):E5212–E5221
- Fu L et al (2017) Comparison of neurotoxicity of different aggregated forms of Abeta40, Abeta42 and Abeta43 in cell cultures. *J Pept Sci* 23(3):245–251
- Gastpar R et al (2005) Heat shock protein 70 surface-positive tumor exosomes stimulate migratory and cytolytic activity of natural killer cells. *Cancer Res* 65(12):5238–5247
- Guzhova I et al (2001) In vitro studies show that Hsp70 can be released by glia and that exogenous Hsp70 can enhance neuronal stress tolerance. *Brain Res* 914(1–2):66–73
- Haass C, Selkoe DJ (2007) Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide. *Nat Rev Mol Cell Biol* 8(2):101–112
- Harper JD, Lieber CM, Lansbury PT Jr (1997) Atomic force microscopic imaging of seeded fibril formation and fibril branching by the Alzheimer's disease amyloid-beta protein. *Chem Biol* 4(12):951–959
- Heydari AR, Conrad CC, Richardson A (1995) Expression of heat shock genes in hepatocytes is affected by age and food restriction in rats. *J Nutr* 125(3):410–418
- Hightower LE, Guidon PT Jr (1989) Selective release from cultured mammalian cells of heat-shock (stress) proteins that resemble gliaxon transfer proteins. *J Cell Physiol* 138(2):257–266
- Hoshino T et al (2011) Suppression of Alzheimer's disease-related phenotypes by expression of heat shock protein 70 in mice. *J Neurosci* 31(14):5225–5234
- Jang H et al (2010) beta-Barrel topology of Alzheimer's beta-amyloid ion channels. *J Mol Biol* 404(5):917–934
- Kampinga HH et al (2009) Guidelines for the nomenclature of the human heat shock proteins. *Cell Stress Chaperones* 14(1):105–111
- Kanekiyo T et al (2013) Neuronal clearance of amyloid-beta by endocytic receptor LRP1. *J Neurosci* 33(49):19276–19283
- Kawahara M, Arispe N, Kuroda Y, Rojas E (1997) Alzheimer's disease amyloid beta-protein forms Zn(2+)-sensitive, cation-selective channels across excised membrane patches from hypothalamic neurons. *Biophys J* 73(1):67–75
- King M et al (2009) The small heat shock protein Hsp27 protects cortical neurons against the toxic effects of beta-amyloid peptide. *J Neurosci Res* 87(14):3161–3175
- Kirby BA et al (1994) Heat shock proteins protect against stress-related phosphorylation of tau in neuronal PC12 cells that have acquired thermotolerance. *J Neurosci* 14(9):5687–5693
- Kirkitadze MD, Bitan G, Teplow DB (2002) Paradigm shifts in Alzheimer's disease and other neurodegenerative disorders: the emerging role of oligomeric assemblies. *J Neurosci Res* 69(5):567–577
- Kotler SA et al (2014) Differences between amyloid-beta aggregation in solution and on the membrane: insights into elucidation of the mechanistic details of Alzheimer's disease. *Chem Soc Rev* 43(19):6692–6700
- Lambert MP et al (1998) Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. *Proc Natl Acad Sci U S A* 95(11):6448–6453
- Lee M et al (2016) Conformational changes of Abeta (1–42) monomers in different solvents. *J Mol Graph Model* 65:8–14
- Lin H, Arispe NJ (2015) Single-cell screening of cytosolic [Ca(2+)] reveals cell-selective action by the Alzheimer's Abeta peptide ion channel. *Cell Stress Chaperones* 20(2):333–342

- Lindquist S, Craig EA (1988) The heat-shock proteins. *Annu Rev Genet* 22:631–677
- Liu CC et al (2017) Astrocytic LRP1 mediates brain A $\beta$  clearance and impacts amyloid deposition. *J Neurosci* 37(15):4023–4031
- Lobello K et al (2012) Targeting beta amyloid: a clinical review of immunotherapeutic approaches in Alzheimer's disease. *Int J Alzheimers Dis* 2012:628070
- Mansson C et al (2014) Interaction of the molecular chaperone DNAJB6 with growing amyloid-beta 42 (A $\beta$ 42) aggregates leads to sub-stoichiometric inhibition of amyloid formation. *J Biol Chem* 289(45):31066–31076
- Marini AM et al (1990) 70-kilodalton heat shock protein induction in cerebellar astrocytes and cerebellar granule cells in vitro: comparison with immunocytochemical localization after hyperthermia in vivo. *J Neurochem* 54(5):1509–1516
- Muchowski PJ, Wacker JL (2005) Modulation of neurodegeneration by molecular chaperones. *Nat Rev Neurosci* 6(1):11–22
- Nitta A et al (1994) beta-Amyloid protein-induced Alzheimer's disease animal model. *Neurosci Lett* 170(1):63–66
- Njemini R et al (2011a) Circulating heat shock protein 70 in health, aging and disease. *BMC Immunol* 12:24
- Njemini R et al (2011b) Circulating heat shock protein 70 (Hsp70) in elderly members of a rural population from Cameroon: association with infection and nutrition. *Arch Gerontol Geriatr* 53(3):359–363
- Ojha J et al (2011) Sequestration of toxic oligomers by HspB1 as a cytoprotective mechanism. *Mol Cell Biol* 31(15):3146–3157
- Pahlavani MA et al (1995) The expression of heat shock protein 70 decreases with age in lymphocytes from rats and rhesus monkeys. *Exp Cell Res* 218(1):310–318
- Rea IM, McNerlan S, Pockley AG (2001) Serum heat shock protein and anti-heat shock protein antibody levels in aging. *Exp Gerontol* 36(2):341–352
- Roche J et al (2016) Monomeric A $\beta$ (1–40) and A $\beta$ (1–42) peptides in solution adopt very similar Ramachandran map distributions that closely resemble random coil. *Biochemistry* 55(5):762–775
- Roychaudhuri R et al (2009) Amyloid beta-protein assembly and Alzheimer disease. *J Biol Chem* 284(8):4749–4753
- Sciaccia MF et al (2012) Two-step mechanism of membrane disruption by A $\beta$  through membrane fragmentation and pore formation. *Biophys J* 103(4):702–710
- Selkoe DJ, Hardy J (2016) The amyloid hypothesis of Alzheimer's disease at 25 years. *EMBO Mol Med* 8(6):595–608
- Seo J et al (2017) An infrared spectroscopy approach to follow beta-sheet formation in peptide amyloid assemblies. *Nat Chem* 9(1):39–44
- Shafirir Y et al (2010a) Beta-barrel models of soluble amyloid beta oligomers and annular protofibrils. *Proteins* 78(16):3458–3472
- Shafirir Y et al (2010b) Models of membrane-bound Alzheimer's A $\beta$  peptide assemblies. *Proteins* 78(16):3473–3487
- Shibata M et al (2000) Clearance of Alzheimer's amyloid-ss(1–40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier. *J Clin Invest* 106(12):1489–1499
- Shoji M et al (2001) The levels of cerebrospinal fluid A $\beta$ 40 and A $\beta$ 42(43) are regulated age-dependently. *Neurobiol Aging* 22(2):209–215
- Simakova O, Arispe NJ (2006) Early and late cytotoxic effects of external application of the Alzheimer's A $\beta$  result from the initial formation and function of A $\beta$  ion channels. *Biochemistry* 45(18):5907–5915
- Simakova O, Arispe NJ (2007) The cell-selective neurotoxicity of the Alzheimer's A $\beta$  peptide is determined by surface phosphatidylserine and cytosolic ATP levels. Membrane binding is required for A $\beta$  toxicity. *J Neurosci* 27(50):13719–13729
- Sprang GK, Brown IR (1987) Selective induction of a heat shock gene in fibre tracts and cerebellar neurons of the rabbit brain detected by in situ hybridization. *Brain Res* 427(1):89–93
- Thinakaran G, Koo EH (2008) Amyloid precursor protein trafficking, processing, and function. *J Biol Chem* 283(44):29615–29619
- Toth ME et al (2013) Overexpression of Hsp27 ameliorates symptoms of Alzheimer's disease in APP/PS1 mice. *Cell Stress Chaperones* 18(6):759–771
- Zhao LN et al (2012) The toxicity of amyloid beta oligomers. *Int J Mol Sci* 13(6):7303–7327